Schrodinger, Inc. 8-K

What Happened
Schrödinger, Inc. announced on June 29, 2026 (Form 8-K) that it received a cash payment of approximately $57 million in connection with Eli Lilly & Company’s completion of its acquisition of Ajax Therapeutics, Inc., a company co‑founded by Schrödinger. The company also disclosed it is eligible to receive additional cash payments if Ajax achieves specified clinical and regulatory milestones.

Key Details

• Schrödinger received approximately $57.0 million in cash related to the Ajax acquisition.
• Ajax Therapeutics, Inc. was acquired by Eli Lilly; Ajax was co‑founded by Schrödinger.
• Schrödinger may receive additional contingent cash payments tied to specified clinical and regulatory milestones.
• The disclosure was furnished under Regulation FD on June 29, 2026 and is not “filed” for purposes of Section 18 of the Exchange Act (limited incorporation/ liability).

Why It Matters
This is a material cash receipt that increases Schrödinger’s near‑term cash resources and creates the possibility of future milestone‑based payments if Ajax meets development or regulatory goals. For investors, the item is a one‑time cash inflow (with potential contingent upside) rather than an operating revenue announcement; the company also framed the disclosure as Regulation FD furnished information, not a filed submission.